Research progress on the related treatment of progressive myoclonic epilepsy
10.12092/j.issn.1009-2501.2023.10.013
- Author:
Yangbin DANG
1
;
Yuxin LIANG
1
;
Tiancheng WANG
1
Author Information
1. Epilepsy Center, Department of Neurology, Lanzhou University Second Hospital
- Publication Type:Journal Article
- Keywords:
antiseizure medications;
progress;
progressive myoclonic epilepsy;
treatment
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(10):1184-1194
- CountryChina
- Language:Chinese
-
Abstract:
Progressive myoclonic epilepsy (PME) is a rare epileptic syndrome closely associated with genetic factors. The disease is primarily inherited in an autosomal recessive manner, although there are rare cases that demonstrate autosomal dominant or mitochondrial inheritance. Common clinical features include myoclonus, multiple seizure types, and progressive decline in neurological and cognitive function. PME typically manifests in late childhood or adolescence but can occur at any age. It accounts for approximately 1% of epileptic syndromes among children and adolescents worldwide. In recent years, in addition to antiseizure medications, numerous non-pharmacological treatments have emerged, including dietary therapy, neuromodulatory therapy, immunomodulatory therapy, enzyme replacement therapy, gene therapy, etc. This article aims to review the research progress in the treatment of PME.
